[11C]5-Hydroxy-tryptophan Positron Emission Tomography for Assessment of Islet Mass During Progression of Type 2 Diabetes
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 39
- 主要终点
- [11C]5-hydroxy-tryptophan Uptake in the Pancreas
研究概览
简要总结
Cross-sectional study to investigate subjects at different stages of type 2 diabetes development with expected stratification of pancreatic islet mass. Non-diabetic individuals were assigned as control. The primary outcome was the [11C]5-hydroxy-tryptophan uptake and retention in the pancreas as a surrogate marker for the endogenous islet mass.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Type 2 diabetes fulfilling criteria for the four different study groups, or healthy volunteers
排除标准
- •Ongoing pregnancy
- •Renal failure (GFR<60 ml/min)
- •Magnetic metal parts in the body
- •Ongoing treatment with selective serotonin receptor inhibitors
研究组 & 干预措施
Healthy control
Healthy control
干预措施: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan (Radiation)
Obese with oral antidiabetic drugs
BMI>30, Type 2 diabetes treated with oral antidiabetic drugs
干预措施: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan (Radiation)
Obese, treated with oral antidiabetic drugs + insulin
BMI>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
干预措施: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan (Radiation)
Normal weight, treated with oral antidiabetic drugs
BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
干预措施: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan (Radiation)
Normal weight, treated with oral antidiabetic drugs + insulin
BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
干预措施: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan (Radiation)
结局指标
主要结局
[11C]5-hydroxy-tryptophan Uptake in the Pancreas
时间窗: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
Uptake of tracer with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release
次要结局
- Pancreatic Volume(Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release)
- Pancreatic Fat Content(Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release)
- Hepatic Fat Content(Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release)
- Pancreatic Perfusion(Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release)
研究者
Per-Ola Carlsson
Professor, Senior consultant
Uppsala University Hospital